In this episode, Karen Bigman, MBA, joins to discuss sexual health, intimacy, and relationship challenges facing adults as they navigate midlife and beyond.
|Articles|January 20, 2005
Hormone therapy significantly increases risk of bone fractures
The risk of bone fractures increases for those prostate cancer patients on androgen-deprivation therapy by more than 40%, according an article in last week's New England Journal of Medicine (2005; 352:154-64).
Advertisement
Advertisement
Related to this article
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma
2
FDA grants priority review to perioperative durvalumab plus enfortumab vedotin in MIBC
3
After curative-intent treatment, prostate cancer recurrence is still an unmet need
4
Sandip Prasad, MD, on patient selection for chemoablation in LG-IR-NMIBC
5